Mitsubishi Tanabe Pharma Corporation Patent applications |
Patent application number | Title | Published |
20160108078 | GLUCOPYRANOSIDE COMPOUND - A compound of the formula: | 04-21-2016 |
20160002276 | METHOD FOR PRODUCING a-HALO-TETRAACYL-GLUCOSE - There is provided an efficient and excellent preparation method of an α-halo-tetraacyl-glucose which is suitable for industrial preparation, which comprises reacting D-glucose or lower alkyl D-glucoside with a reactive derivative of a carboxylic acid and a metal halide to prepare the α-halo-tetraacyl-glucose represented by the formula (III): | 01-07-2016 |
20150239889 | PYRAZOLOPYRIMIDINE COMPOUND - Provided is a pyrazolopyrimidine compound represented by formula (I) having an HIF-PHD inhibitory effect, or a pharmaceutically acceptable salt thereof. | 08-27-2015 |
20150232459 | NOVEL RENIN INHIBITOR - The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. | 08-20-2015 |
20150218143 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY - Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: | 08-06-2015 |
20150218113 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND - The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. | 08-06-2015 |
20150182602 | PHARMACEUTICAL FORMULATIONS COMPRISING PARAOXONASE - The present invention provides a pharmaceutical formulation comprising paraoxonase (PON), a purification and stabilization method of PON, and an agent for prophylactic and/or therapeutic treatment of a disease resulting from ischemia reperfusion and/or cerebral infarction containing PON as an active ingredient. | 07-02-2015 |
20150158844 | AROMATIC HETEROCYCLIC COMPOUND - The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR | 06-11-2015 |
20150152082 | METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND - The present invention provides an industrially advantageous method for producing an optically active naphthalene compound useful as a therapeutic agent for dermatitis or the like. Specifically, the present invention provides a method for producing an optically active naphthalene compound [I], which comprises: a step of reacting a compound [a-1] and a compound [b-1] with each other in the presence of a base and a catalyst that is composed of a Pd compound and a tertiary phosphine ligand (step a); a step of asymmetrically hydrogenating a compound [c-1] in the presence of a hydrogen donor and a complex that is prepared from a ruthenium compound and a chiral ligand, or alternatively in the presence of an optically active oxazaborolidine compound (a CBS catalyst) and a boron hydride compound (step b); and a step of treating a compound [d-1] with a reducing agent (step c). (In the above formulae, R | 06-04-2015 |
20150105400 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-β, IL-1β, IL-6 and MCP-1 and the like. | 04-16-2015 |
20150104483 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-α, IL-1β, IL-6 and MCP-1 and the like. | 04-16-2015 |
20150087620 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES - The present invention provides a compound represented by the following formula (I): | 03-26-2015 |
20150065715 | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF - The present invention relates to novel amidopyridine derivatives. More specifically, the present invention provides a medicinal agent which is useful as a prophylactic or therapeutic agent for diseases based on the production of cytokines from T cells, comprising as the active ingredient an amidopyridine derivative or a pharmacologically acceptable salt thereof. Provided are an amidopyridine derivative of the following general formula (I): | 03-05-2015 |
20140350250 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-α, IL-1β, IL-6 and MCP-1 and the like. | 11-27-2014 |
20140350249 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-α, IL-1β, IL-6 and MCP-1 and the like. | 11-27-2014 |
20140194407 | NOVEL ANTIPLATELET AGENT - The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I: | 07-10-2014 |
20140121240 | NOVEL PHARMACEUTICAL COMPOSITION - Provided is a novel pharmaceutical composition (antipruritic agent) that is useful for prophylaxis or treatment of itch in conditions such as dermal pruritus. More specifically, provided is a pharmaceutical composition (antipruritic agent) for treatment of itch comprising as an active ingredient a naphthalene compound of the following formula (I): | 05-01-2014 |
20140080770 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME - An arylalkylamine compound is represented by the following formula [I-e] or a pharmaceutically acceptable salt thereof. | 03-20-2014 |
20140073671 | ORALLY DISINTEGRATING TABLET - Provided is an orally disintegrating tablet comprising a bitter-tasting pharmaceutically active ingredient in the form of bepotastine or a pharmacologically acceptable salt thereof that enables the bitter taste thereof to be masked, has both superior oral cavity disintegration and adequate hardness, and can be produced with ordinary tablet production equipment. The present invention relates to an orally disintegrating tablet containing bepotastine or a pharmacologically acceptable salt thereof, menthol or cyclodextrin, a water-insoluble polymer, and a disintegrating agent; and a method for producing an orally disintegrating tablet, comprising: 1) a step for obtaining granulated granules by mixing and granulating bepotastine or a pharmacologically acceptable salt thereof, a water-insoluble polymer, and optionally a vehicle, 2) a step for obtaining granules for tableting by mixing the granulated granules, menthol, a disintegrating agent, and optionally a lubricant and/or sweetener, and 3) a step for compressing the granules for tableting. | 03-13-2014 |
20140018387 | OINTMENT WITH EXCELLENT FORMULATION STABILITY - Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene•3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant. | 01-16-2014 |
20130288908 | POLYNUCLEOTIDE CONSTRUCT CAPABLE OF DISPLAYING FAB IN A CELL-FREE TRANSLATION SYSTEM, AND METHOD FOR MANUFACTURING AND SCREENING FAB USING SAME - The polynucleotide construct of (1) or (2) below is used to perform ribosome display, CIS display and/or mRNA display in order to screen a Fab against an antigen of interest: (1) a polynucleotide construct which monocistronically comprises a ribosome-binding sequence, Fab first chain-coding sequence, linker peptide-coding sequence, Fab second chain-coding sequence and scaffold-coding sequence in this order, and further comprises at its 3′-end a structure necessary for maintaining a complex with the Fab encoded by itself, and (2) a polynucleotide construct which comprises a Fab first chain-expressing cistron and a Fab second chain-expressing cistron each containing a ribosome-binding sequence, a Fab first chain-coding sequence or Fab second chain-coding sequence, and a scaffold-coding sequence in this order, the first Fab-expressing cistron further comprising at its 3′-end a ribosome stall sequence, said Fab second chain-expressing cistron further comprising at its 3′-end a structure necessary for maintaining a complex with the Fab encoded by itself. | 10-31-2013 |
20130261128 | CONTINUOUS ARYCYCLIC COMPOUND - This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. | 10-03-2013 |
20130237708 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same - The present invention relates to a method for preparing an optically active cyclic alcohol compound represented by general formula [I]: | 09-12-2013 |
20130211075 | AMIDE DERIVATIVE AND USE THEREOF - The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) | 08-15-2013 |
20130150374 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME - The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. | 06-13-2013 |
20130040930 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE - Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) | 02-14-2013 |
20130034607 | TABLET - The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge. | 02-07-2013 |
20120328633 | T CELL ACTIVATION INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND SCREENING METHOD FOR T CELL ACTIVATION INHIBITING SUBSTANCE - Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM. | 12-27-2012 |
20120323178 | BEPOTASTINE COMPOSITIONS - Novel compositions including bepotastine besilate and a corticosteroid are provided, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV. | 12-20-2012 |
20120288482 | THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION - The present invention aims to provide a means for effectively and conveniently treating diseases wherein corneal endothelial cells poor in proliferative capacity in vivo are damaged. The present invention provides a therapeutic agent for corneal endothelial dysfunction containing (R)-(+)-N-(1H-pyrrolo [2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide or a pharmacologically acceptable salt thereof (compound (Ia)) as active ingredient, an agent for promoting adhesion of corneal endothelial cells, containing compound (Ia), a culture medium for corneal endothelial cells, containing the agent for promoting adhesion, an implant for corneal endothelial keratoplasty, containing corneal endothelial cells, scaffold and compound (Ia), and a production method of a corneal endothelial preparation, including a step of cultivating corneal endothelial cells using the culture medium. | 11-15-2012 |
20120276166 | ELUTION-STABILIZED PREPARATION - The invention provides a solid preparation which does not undergo the delay of elution of the active ingredient even after long-term storage. The solid preparation independently contains a teneligliptin-containing part containing teneligliptin or a salt thereof, or a solvate of teneligliptin or the salt thereof, in an amount 1.5- to 10-fold larger than that desired for the solid preparation. | 11-01-2012 |
20120271270 | PLASTIC CONTAINER COMPRISING CYCLIC POLYOLEFIN LAYER - The present invention provides and a plastic container and multilayered films, which comprises a heat-sealable seal layer, a cyclic polyolefin layer, and an outermost layer, wherein the seal layer comprises polypropylene, the cyclic polyolefin layer comprises a cyclic polyolefin polymer or a cyclic polyolefin copolymer, and the outermost layer comprises a layer containing polypropylene, and which further comprises a resin composition layer comprises a blended product of a propylene polymer and a styrene elastomer. The plastic container of the present invention can suppresses a reduction in the medicament content of a liquid-state medicament and is excellent in terms of shock resistance, handling ability during the filling of the container with the medicament, and the moldability and transparency of the container. | 10-25-2012 |
20120252812 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE - A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: | 10-04-2012 |
20120232283 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE - The invention provides a production method of a biaryltetrazole derivative useful as an intermediate for an angiotensin II receptor antagonist. The method comprises reacting an aryltetrazole derivative with a benzene derivative, deprotecting or reducing the resulting compound, and halogenating the deprotected or reduced compound | 09-13-2012 |
20120225905 | BEPOTASTINE COMPOSITIONS - Novel compositions including bepotastine besilate are provided such as sorbitol-free compositions, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV. | 09-06-2012 |
20120220623 | THE ENANTIOMER OF TENATOPRAZOLE AND THE USE THEREOF IN THERAPY - This invention relates to optically active substances of tenatoprazole, (+) and (−)-5-methoxy-2-{(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridine. The compound and pharmaceutical compositions thereof are useful for anti-ulcer agent. | 08-30-2012 |
20120220591 | PYRIMIDONE COMPOUNDS - A pyrimidone derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof: | 08-30-2012 |
20120208797 | PYRIMIDONE DERIVATIVES - A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: | 08-16-2012 |
20120196824 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) | 08-02-2012 |
20120135947 | OIL-IN-WATER EMULSION COMPOSITION CONTAINING DIFLUPREDNATE AND TOBRAMYCIN - The present invention provides an oil-in-water emulsion composition for topical administration, containing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier. Moreover, it provides a method for stabilizing tobramycin, which includes mixing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier to form an oil-in-water emulsion. The present invention can provide an oil-in-water emulsion composition containing tobramycin, which can maintain tobramycin content stably even when a non-ionic surfactant is added. | 05-31-2012 |
20120135534 | ADSORPTION TEST METHOD OF SPHERICAL CARBON ADSORBENT - The present invention relates to an adsorption test method of a spherical carbon adsorbent, particularly Kremezin, which includes evaluating a test solution containing one or more kinds of particular uremic toxins or related compounds for the adsorbability, namely, adsorption titer, adsorption speed and/or adsorption selectivity, of the spherical carbon adsorbent. | 05-31-2012 |
20120129812 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST - Provided is a heterocyclic derivative showing a thyroid hormone β receptor agonist action, which is effective for the prophylaxis or treatment of the diseases relating to the action. A compound represented by the formula [I]: | 05-24-2012 |
20120095216 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES - A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: | 04-19-2012 |
20120064570 | NOVEL CELL PENETRATING PEPTIDE - According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide. | 03-15-2012 |
20110294786 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 12-01-2011 |
20110282058 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF - The present invention provides 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin- | 11-17-2011 |
20110263571 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE - Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) | 10-27-2011 |
20110257392 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF - The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: | 10-20-2011 |
20110251385 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF - The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: | 10-13-2011 |
20110224220 | SUBSTITUTED TRICYCLIC DERIVATIVES - Compounds of formula (I): | 09-15-2011 |
20110144138 | SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES - Pyrimido isoquinoline derivatives represented by formula (I): | 06-16-2011 |
20110144133 | SUBSTITUTED PYRIMIDONE DERIVATIVES - Pyrimidone derivatives of formula (I) | 06-16-2011 |
20110144132 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 06-16-2011 |
20110144114 | SUBSTITUTED TRIAZINONE DERIVATIVES - Triazinone derivatives represented by formula (I) | 06-16-2011 |
20110144092 | SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 06-16-2011 |
20110136828 | SUBSTITUTED N-OXIDE PYRAZINE DERIVATIVES - N-oxide pyrazine derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 06-09-2011 |
20110130419 | NOVEL SALT OF ISOQUINOLINE COMPOUND AND CRYSTAL THEREOF - The invention provides a salt of (R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one and a crystal thereof. (R)-3-[2-(2-Hydroxymethylpyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one monophosphate is a compound which is chemically stable, has high solubility, and shows less weight change due to humidity as compared to a free form and monohydrochloride dihydrate, and is superior as a bulk drug for pharmaceutical products. | 06-02-2011 |
20110068037 | PLASTIC CONTAINER COMPRISING CYCLIC POLYOLEFIN LAYER - The present invention provides and a plastic container and multilayered films, which comprises a heat-sealable seal layer, a cyclic polyolefin layer, and an outermost layer, wherein the seal layer comprises polypropylene, the cyclic polyolefin layer comprises a cyclic polyolefin polymer or a cyclic polyolefin copolymer, and the outermost layer comprises a layer containing polypropylene, and which further comprises a resin composition layer comprises a blended product of a propylene polymer and a styrene elastomer. The plastic container of the present invention can suppresses a reduction in the medicament content of a liquid-state medicament and is excellent in terms of shock resistance, handling ability during the filling of the container with the medicament, and the moldability and transparency of the container. | 03-24-2011 |
20110039835 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES - The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 02-17-2011 |
20110034440 | HOMOCYSTEINE SYNTHASE INHIBITOR - The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) | 02-10-2011 |
20110034435 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS - A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R | 02-10-2011 |
20110021773 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE - A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: | 01-27-2011 |
20110015187 | SUBSTITUTED HETEROARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES - The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 01-20-2011 |
20110015177 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES - The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 01-20-2011 |
20110015176 | SUBSTITUTED HETEROARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES - The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 01-20-2011 |
20100320215 | PLASTIC CONTAINER COMPRISING CYCLIC POLYOLEFIN LAYER - The present invention provides and a plastic container and multilayered films, which comprises a heat-sealable seal layer, a cyclic polyolefin layer, and an outermost layer, wherein the seal layer comprises polypropylene, the cyclic polyolefin layer comprises a cyclic polyolefin polymer or a cyclic polyolefin copolymer, and the outermost layer comprises a layer containing polypropylene, and which further comprises a resin composition layer comprises a blended product of a propylene polymer and a styrene elastomer. The plastic container of the present invention can suppresses a reduction in the medicament content of a liquid-state medicament and is excellent in terms of shock resistance, handling ability during the filling of the container with the medicament, and the moldability and transparency of the container. | 12-23-2010 |
20100305159 | CRYSTALLINE FORM OF PIPERIDINE COMPOUND - The present invention is to provide a crystalline form of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine or a solvate thereof. | 12-02-2010 |
20100305139 | METHOD OF TREATING ABNORMAL LIPID METABOLISM - The present invention provides a pharmaceutical agent for the treatment and/or prophylaxis of abnormal blood glucose and lipid metabolism associated with eating, for which a sufficient treatment method or a therapeutic drug has not been found. | 12-02-2010 |
20100286127 | ANTITUMOR AGENT - The present invention relates to a novel antitumor agent containing a compound that inhibits binding between acetylated histone and a bromodomain-containing protein, preferably a thienotriazolodiazepine compound represented by the following formula (I) | 11-11-2010 |
20100228026 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF - The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effect(s) on various diseases due to its agonist action at AT | 09-09-2010 |
20100226974 | ANTIBODY RECOGNIZING ANTIGEN - The invention provides antibodies against a non-muscular myosin heavy chain type A or a mutant thereof, and F(ab′) | 09-09-2010 |
20100184221 | METHOD FOR ISOLATION OF CELL, SERUM-FREE CULTURE MEDIUM FOR CELL, AND METHOD FOR CULTURE OF CELL - The present invention provides a method for isolating cells, in particular, stem cells, which method comprises the steps of: dissociating cells from a tissue of animal origin; seeding and incubating the cells in a culture vessel with no surface treatment; and selecting cells adhered to the vessel. | 07-22-2010 |
20100179157 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. | 07-15-2010 |
20100152261 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND - A nitrogen-containing heterocyclic derivative represented by the following general formula (I), or a hydrate or solvate thereof, which has a selective antagonistic action on the muscarinic M | 06-17-2010 |
20100113775 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS - A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein each R | 05-06-2010 |
20100087461 | ARYLAMIDE PYRIMIDONE COMPOUNDS - The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 04-08-2010 |
20100087460 | ARYLAMIDE PYRIMIDONE DERIVATIVES - The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 04-08-2010 |
20100087449 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS - The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 04-08-2010 |
20100081677 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES - The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 04-01-2010 |
20100063055 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES - The problem of the present invention is to provide a compound having a GR selective binding activity, which shows less action on other nuclear receptors such as progesterone receptor (PR), mineralocorticoid receptor (MR) and the like. The present invention provides a condensed tetrahydroquinoline compound represented by the following formula (I) | 03-11-2010 |
20100048487 | NOVEL CELL PENETRATING PEPTIDE - According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide. | 02-25-2010 |
20100041643 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF - [Solving means] A thienotriazolodiazepine compound of the following formula (I) | 02-18-2010 |
20090325207 | NOVEL PHOSPHODIESTERASE AND GENE THEREOF - The present invention is to provide a novel phosphodiesterase and a gene thereof, specifically, Type 11 phosphodiesterase (PDE11) and a gene thereof, more specifically, a phosphodiesterase selected from (A) a protein having an amino acid sequenced shown by SEQ.ID.NO: 2, SEQ.ID.NO: 4, SEQ.ID.NO: 6 or SEQ.ID.NO: 39, and (B) a protein having an amino acid sequence shown by SEQ.ID.NO: 2, SEQ.ID.NO: 4, SEQ.ID.NO: 6 or SEQ.ID.NO: in which one or several amino acids are deleted, substituted or added, and having an activity of hydrolyzing a cyclic nucleotide, and a gene thereof, and a method of characterizing, identifying and selecting a phosphodiesterase inhibitor by using the same. | 12-31-2009 |
20090306088 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof are disclosed and claimed. | 12-10-2009 |
20090292125 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES - The present invention is to provide a process for preparing optically active tetrahydroquinoline derivatives which can be used for the treatment and/or prevention of diseases such as arteriosclerotic diseases, dyslipidemia and the like, and a process for preparing synthetic intermediates thereof. | 11-26-2009 |
20090281121 | SUBSTITUTED 8-PIPERIDINYL-2-PYRIDINYL-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE AND 8-PIPERIDINYL-2-PYRIMIDINYL-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE DERIVATIVES - The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof: | 11-12-2009 |
20090281095 | THIOMORPHOLINE COMPOUND AND PROCESS FOR PREPARING THE SAME - The present invention discloses a thiomorpholine compound represented by the formula [I]: | 11-12-2009 |
20090156804 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF - The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: | 06-18-2009 |
20090137530 | Amine Compound and Use Thereof for Medical Purposes - A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. | 05-28-2009 |
20090110655 | PROPHYLACTIC AND/OR THERAPEUTIC DRUG FOR NONALCOHOLIC STEATOHEPATITIS - The present invention provides a method for the treatment of nonalcoholic steatohepatitis with a pharmaceutically acceptable anion exchange resin such as, for example, colestimide. | 04-30-2009 |
20090088449 | 4-ACYLAMINOPYRIDINE DERIVATIVE MEDIATED NEUROGENESIS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes methods based on use of a 4-acylaminopyridine derivative to stimulate or activate the formation of new nerve cells. | 04-02-2009 |
20090088442 | PROPHYLACTIC/THERAPEUTIC AGENT FOR ABNORMALITIES OF SUGAR/LIPID METABOLISM - The present invention provides a pharmaceutical agent for the treatment and/or prophylaxis of abnormal blood glucose and lipid metabolism associated with eating, for which a sufficient treatment method or a therapeutic drug has not been found. | 04-02-2009 |
20090082311 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes - The present invention provides a novel compound having few side effects such as bradycardia and the like and having superior peripheral blood lymphocyte-decreasing effect. | 03-26-2009 |
20090082256 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF - A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and | 03-26-2009 |
20090076276 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF - The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. | 03-19-2009 |
20090053300 | MONOCLONAL ANTIBODY, GENE ENCODING THE ANTIBODY, HYBRIDOMA, PHARMACEUTICAL COMPOSITION, AND DIAGNOSTIC REAGENT - Disclosed is a monoclonal antibody which has a heavy chain variable region containing amino acid sequences depicted in SEQ ID NOs:74, 76 and 78 and a light chain variable region containing amino acid sequences depicted in SEQ ID NOs:80, 82 and 84. The monoclonal antibody can be used as a cancer therapeutic agent which acts selectively on a cancer tissue of non-small lung cancer, pancreatic cancer, gastric cancer or the like. | 02-26-2009 |
20090036427 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 02-05-2009 |
20090029994 | Trisubstituted amine compound - The present invention relates to a compound of the general formula (1): | 01-29-2009 |
20090023729 | Trisubstituted amine compound - The present invention relates to a compound of the general formula (1): | 01-22-2009 |